Experimental cell therapy targets Hard-to-Treat myeloma

NCT ID NCT04960579

Ongoing Disease control Sponsor: Poseida Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new therapy called P-BCMA-ALLO1 for people with multiple myeloma that has come back or not responded to standard treatments. The therapy uses donor immune cells that are engineered to find and attack myeloma cells. The main goals are to check safety and find the best dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: P-BCMA-ALLO1 (a type of immune cell therapy that targets cancer cells)
What this could lead to: If successful, this could provide a new treatment option for patients with multiple myeloma that has not responded to other therapies.
What could go wrong: This is an early-phase trial, so the therapy may not work or could cause serious side effects like cytokine release syndrome. It is not yet proven to be safe or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Advocate Aurora Health

Park Ridge, Illinois, 66068, United States
Blood Marrow and Transplant Group of Georgia

Atlanta, Georgia, 30342, United States
City of Hope

Goodyear, Arizona, 85338, United States
City of Hope

Chicago, Illinois, 60099, United States
Cleveland Clinic

Cleveland, Ohio, 44195, United States
Emory University

Atlanta, Georgia, 30322, United States
Hackensack Meridian Health

Hackensack, New Jersey, 07601, United States
Houston Methodist Research Institute

Houston, Texas, 77030, United States
Mount Sinai

New York, New York, 10029, United States
Roswell Park Comprehensive Cancer Center

Buffalo, New York, 14263, United States
Sarah Cannon Research Institute - Methodist Healthcare

San Antonio, Texas, 78229, United States
Sarah Cannon Research Institute - St. David's South Austin Medical Center

Austin, Texas, 78704, United States
University of California San Diego

San Diego, California, 92093, United States
University of California San Francisco

San Francisco, California, 94143, United States
University of Cincinnati

Cincinnati, Ohio, 45221, United States
University of Iowa

Iowa City, Iowa, 52242, United States
University of Kansas Medical Center

Kansas City, Kansas, 66160, United States
University of Maryland Greenebaum Comprehensive Cancer Center

Baltimore, Maryland, 21201, United States
University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27599-1350, United States
University of Oklahoma, Health Sciences Center

Oklahoma City, Oklahoma, 73104, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19104-4238, United States
Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States
Wayne State - Karmanos Cancer Institute

Detroit, Michigan, 48201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.